Advances in research on human rhinovirus
10.3760/cma.j.cn112866-20220928-00200
- VernacularTitle:人鼻病毒的研究进展
- Author:
Qing WANG
1
;
Ming LUO
;
Xue WANG
;
Fang HUANG
;
Cheng GONG
Author Information
1. 首都医科大学公共卫生学院，北京 100069
- Keywords:
Human rhinovirus;
Respiratory infection;
Genotype
- From:
Chinese Journal of Experimental and Clinical Virology
2023;37(2):216-221
- CountryChina
- Language:Chinese
-
Abstract:
Human rhinovirus (HRV) is one of the most common pathogens of acute respiratory infection with a high incidence, which usually cause common colds, but can sometimes cause severe lower respiratory tract infections. In China, the detection rate of HRV was approximately 16.7% from 2009 to 2019, ranking the third in the pathogen spectrum of viral respiratory tract infections. Children under 3 years of age are the main susceptible population. According to its phylogenetic characteristics, HRV can be divided into three species (HRV-A, HRV-B, HRV-C), and can be further classified into 169 genotypes. HRV-C is considered to be more closely related to childhood asthma. The host cell receptors of the three species of HRV are not identical, which may be the important reason for the differences in their clinical manifestations. As no obvious cell pathogenic effects were observed in the HRV-infected individuals, immune injury is supposed to be probably the main pathogenic mechanism of HRV infection. HRV can co-infect with multiple other respiratory pathogens, however several studies reported that HRV infection can inhibit the secondary infection with influenza virus. HRV-A and HRV-B can be cultured in cell lines, while HRV-C can only be cultured using respiratory epithelium organoid. Up to date, there are still no effective drugs and vaccines against HRV available. This manuscript provides a comprehensive, up-to-date review of the progress in the virological, epidemiological, clinical and pathogenic researches of HRV infection, which contribute to further research and formulation of the prevention and control policy for HRV.
